Last updated: 3 January 2024 at 7:38pm EST

Christopher M Starr Net Worth




The estimated Net Worth of Christopher M Starr is at least $685 Tysiąc dollars as of 31 December 2023. Christopher Starr owns over 2,533 units of Monopar Therapeutics Inc stock worth over $62,071 and over the last 21 years Christopher sold MNPR stock worth over $622,620.

Christopher Starr MNPR stock SEC Form 4 insiders trading

Christopher has made over 21 trades of the Monopar Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Christopher exercised 2,533 units of MNPR stock worth $6,079 on 31 December 2023.

The largest trade Christopher's ever made was selling 33,000 units of Monopar Therapeutics Inc stock on 21 August 2003 worth over $297,000. On average, Christopher trades about 3,592 units every 266 days since 2003. As of 31 December 2023 Christopher still owns at least 25,863 units of Monopar Therapeutics Inc stock.

You can see the complete history of Christopher Starr stock trades at the bottom of the page.



What's Christopher Starr's mailing address?

Christopher's mailing address filed with the SEC is 1000 SKOKIE BLVD SUITE 350, , WILMETTE, IL, 60091.

Insiders trading at Monopar Therapeutics Inc

Over the last 5 years, insiders at Monopar Therapeutics Inc have traded over $1,830,000 worth of Monopar Therapeutics Inc stock and bought 895,199 units worth $6,154,669 . The most active insiders traders include Michael J Brown, Diane Hendricks oraz Pharma Llc Mazar Andrew Pau.... On average, Monopar Therapeutics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $32,266. The most recent stock trade was executed by Andrew Cittadine on 30 June 2024, trading 8,952 units of MNPR stock currently worth $21,485.



What does Monopar Therapeutics Inc do?

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.



What does Monopar Therapeutics Inc's logo look like?

Monopar Therapeutics Inc logo

Complete history of Christopher Starr stock trades at Biomarin Pharmaceutical i Monopar Therapeutics Inc

Data
#
Firma
Osoba
Trans.
Transakcja
Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
31 Dec 2023 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,533 $0.34 $862
31 Dec 2023
25,863
30 Sep 2023 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,533 $0.62 $1,570
30 Sep 2023
23,330
30 Jun 2023 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,534 $0.86 $2,167
30 Jun 2023
20,797
31 Mar 2023 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,533 $1.39 $3,521
31 Mar 2023
18,263
31 Dec 2022 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,859 $2.37 $6,776
31 Dec 2022
15,730
30 Sep 2022 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,859 $1.52 $4,346
30 Sep 2022
12,871
30 Jun 2022 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,859 $2.30 $6,575
30 Jun 2022
10,012
31 Mar 2022 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 2,859 $2.55 $7,290
31 Mar 2022
7,153
31 Dec 2021 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 751 $3.21 $2,411
31 Dec 2021
4,294
30 Sep 2021 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 751 $4.87 $3,657
30 Sep 2021
3,543
30 Jun 2021 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 752 $5.89 $4,429
30 Jun 2021
2,792
31 Mar 2021 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 751 $6.20 $4,656
31 Mar 2021
2,040
30 Sep 2020 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 644 $5.35 $3,445
30 Sep 2020
1,289
30 Jun 2020 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 323 $7.46 $2,410
30 Jun 2020
645
31 Mar 2020 Christopher M Starr
Dyrektor
Opcja Ćwiczenie 322 $7.17 $2,309
31 Mar 2020
322
1 Dec 2005 Christopher M Starr
Sr. VP i Scientific Operations
Sprzedaż 10,571 $10.00 $105,710
1 Dec 2005
295,176
21 Nov 2005 Christopher M Starr
Sr. VP i Scientific Operations
Sprzedaż 10,571 $10.00 $105,710
21 Nov 2005
300,176
3 Jun 2004 Christopher M Starr
Sr. VP i Scientific Operations
Sprzedaż 10,000 $7.64 $76,400
3 Jun 2004
305,176
2 Apr 2004 Christopher M Starr
Sr. VP i Scientific Operations
Opcja Ćwiczenie 5,570 $4.00 $22,280
2 Apr 2004
320,746
1 Apr 2004 Christopher M Starr
Sr. VP i Scientific Operations
Sprzedaż 5,000 $7.56 $37,800
1 Apr 2004
315,176
21 Aug 2003 Christopher M Starr
Sr. VP i Scientific Operations
Sprzedaż 33,000 $9.00 $297,000
21 Aug 2003
320,176


Monopar Therapeutics Inc executives and stock owners

Monopar Therapeutics Inc executives and other stock owners filed with the SEC include: